Smith Chas P & Associates PA Cpas Cuts Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Smith Chas P & Associates PA Cpas lowered its position in Kenvue Inc. (NYSE:KVUEFree Report) by 27.2% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 32,759 shares of the company’s stock after selling 12,268 shares during the period. Smith Chas P & Associates PA Cpas’ holdings in Kenvue were worth $758,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the company. Cornerstone Wealth Group LLC grew its position in Kenvue by 176.2% in the 1st quarter. Cornerstone Wealth Group LLC now owns 350,371 shares of the company’s stock worth $7,519,000 after purchasing an additional 223,537 shares in the last quarter. NBC Securities Inc. grew its holdings in shares of Kenvue by 8.4% in the first quarter. NBC Securities Inc. now owns 11,301 shares of the company’s stock valued at $242,000 after acquiring an additional 879 shares in the last quarter. Janney Montgomery Scott LLC increased its position in shares of Kenvue by 56.2% during the first quarter. Janney Montgomery Scott LLC now owns 1,840,875 shares of the company’s stock valued at $39,505,000 after acquiring an additional 662,666 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of Kenvue during the first quarter valued at approximately $1,050,000. Finally, Norden Group LLC bought a new stake in Kenvue during the first quarter worth $1,792,000. 97.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on KVUE. UBS Group raised their target price on Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. Royal Bank of Canada lowered shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price objective on the stock. in a research report on Tuesday, September 24th. Jefferies Financial Group began coverage on shares of Kenvue in a research report on Tuesday, September 24th. They set a “buy” rating and a $27.00 target price for the company. JPMorgan Chase & Co. lifted their price target on shares of Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Friday. Finally, Piper Sandler increased their price objective on Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a report on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $22.20.

Check Out Our Latest Analysis on KVUE

Kenvue Price Performance

Kenvue stock opened at $21.46 on Monday. The firm has a market capitalization of $41.09 billion, a P/E ratio of 27.51, a PEG ratio of 2.76 and a beta of 1.40. Kenvue Inc. has a one year low of $17.67 and a one year high of $23.55. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.68. The business has a fifty day moving average price of $22.13 and a 200-day moving average price of $20.18.

Kenvue (NYSE:KVUEGet Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.04. The business had revenue of $4 billion for the quarter, compared to analysts’ expectations of $3.93 billion. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The firm’s quarterly revenue was down .3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.32 EPS. As a group, equities research analysts forecast that Kenvue Inc. will post 1.08 EPS for the current year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 28th. Investors of record on Wednesday, August 14th were paid a dividend of $0.205 per share. The ex-dividend date was Wednesday, August 14th. This represents a $0.82 annualized dividend and a yield of 3.82%. This is a boost from Kenvue’s previous quarterly dividend of $0.20. Kenvue’s payout ratio is currently 105.13%.

Kenvue Company Profile

(Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Recommended Stories

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUEFree Report).

Institutional Ownership by Quarter for Kenvue (NYSE:KVUE)

Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.